Skip to main content

Table 1 Baseline demographics and disease activity

From: Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study

 

At baseline in ReAct

At baseline in ReAlise

Parameter

n

Value

n

Value

Age, y, mean (SD)

6,610

53.7 (13.0)

3,435

54.5 (12.5)

Female, n (%)

6,610

5,332 (80.7)

3,435

2,724 (79.3)

Duration of RA, y, mean (SD)

6,572

10.8 (8.6)

3,423

12.0 (8.6)

Rheumatoid factor positive, n (%)

6,610

4,811 (72.8)

3,429

2,548 (74.2)*

DMARD use at baseline, n (%)

6,610

4,879 (73.8)

3,435

2,636 (76.7)*

SJC (28), mean (SD)

6,607

10.4 (5.8)

3,435

2.2 (3.4)

TJC (28), mean (SD)

6,607

13.5 (7.0)

3,435

3.2 (4.7)

PtGA, mm VAS, mean (SD)

6,568

61.9 (21.4)

3,256

26.2 (23.3)

DAS28 (ESR), mean (SD)

6,554

6.0 (1.1)

2,729

3.5 (1.3)

HAQ DI, mean (SD)

6,560

1.64 (0.68)

3,235

0.89 (0.74)

CRP, mg/L, mean (SD)

6,535

25.7 (30.8)

2,962

9.5 (15.7)

  1. *At time of entry into ReAct study. CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; DMARD, disease-modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; HAQ DI, Health Assessment Questionnaire Disability Index; PtGA, patient global assessment; RA, rheumatoid arthritis; SD, standard deviation; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale.